- Home
- ESTC vs MDGL Comparison
ESTC vs MDGL Comparison
Compare ESTC & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESTC
- MDGL
- Stock Information
- Founded
- ESTC 2012
- MDGL 2011
- Country
- ESTC Netherlands
- MDGL United States
- Employees
- ESTC 3372
- MDGL N/A
- Industry
- ESTC Computer Software: Prepackaged Software
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- ESTC Technology
- MDGL Health Care
- Exchange
- ESTC Nasdaq
- MDGL Nasdaq
- Market Cap
- ESTC 11.7B
- MDGL 7.4B
- IPO Year
- ESTC 2018
- MDGL N/A
- Fundamental
- Price
- ESTC $113.67
- MDGL $320.76
- Analyst Decision
- ESTC Buy
- MDGL Buy
- Analyst Count
- ESTC 26
- MDGL 14
- Target Price
- ESTC $125.42
- MDGL $347.33
- AVG Volume (30 Days)
- ESTC 1.8M
- MDGL 486.2K
- Earning Date
- ESTC 11-21-2024
- MDGL 10-31-2024
- Dividend Yield
- ESTC N/A
- MDGL N/A
- EPS Growth
- ESTC N/A
- MDGL N/A
- EPS
- ESTC 0.57
- MDGL N/A
- Revenue
- ESTC $1,375,737,000.00
- MDGL $76,813,000.00
- Revenue This Year
- ESTC $17.02
- MDGL N/A
- Revenue Next Year
- ESTC $14.03
- MDGL $193.46
- P/E Ratio
- ESTC $200.08
- MDGL N/A
- Revenue Growth
- ESTC 18.71
- MDGL N/A
- 52 Week Low
- ESTC $69.00
- MDGL $168.25
- 52 Week High
- ESTC $136.06
- MDGL $368.29
- Technical
- Relative Strength Index (RSI)
- ESTC 82.45
- MDGL 55.83
- Support Level
- ESTC $109.11
- MDGL $272.72
- Resistance Level
- ESTC $118.18
- MDGL $351.81
- Average True Range (ATR)
- ESTC 3.92
- MDGL 16.32
- MACD
- ESTC 2.10
- MDGL -4.12
- Stochastic Oscillator
- ESTC 87.59
- MDGL 58.28
About ESTC Elastic N.V.
Elastic is a software company based in Mountain View, California, focusing on search-adjacent products. Its search engine allows it to process both structured and unstructured data while gleaning insights from that data. The firm's primary focus is on enterprise search, observability, and security.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.